Skip to Main Content

2,101

Views

0

CrossRef citations to date

0

Altmetric

Original Articles: Clinical Oncology

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy

Tae Min Kima Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of KoreaView further author information

,

Nicolas Girardb Institut Curie, Institute du Thorax Curie-Montsouris, Paris, FranceView further author information

,

Grace Kah Mun Lowc Medical Affairs, Janssen Asia Pacific Medical Affairs, a division of Johnson & Johnson International (Singapore) Pte. LtdCorrespondence[email protected]
View further author information

,

Jianmin Zhuod Statistics and Decision Science, Janssen China Research & Development, ChinaView further author information

,

Dae Young Yue Real World Evidence, Janssen Asia Pacific, Republic of KoreaView further author information

,

Yishen Yangd Statistics and Decision Science, Janssen China Research & Development, ChinaView further author information

,

Maiko Murotaf Global Development, Medical Affair Operations, Janssen Research & Development, Tokyo, JapanView further author information

,

Cindy Thiow Koon Limg Real World Solutions, IQVIA Solutions Asia Pte Ltd, SingaporeView further author information

,

Nora J. Kleinmanh Real World Solutions, IQVIA Hong Kong, Kwai Fong, Hong Kong, P.R. ChinaView further author information

&

Byoung Chul Choi Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of KoreaView further author information